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Abstract 
Alzheimer’s disease (AD) is a severe neurodegenerative disorder, characterized by the 
accumulation of β-amyloid plaques in the extracellular space and an excessive phosphorilation of 
neuronal Tau. Both these factors are believed to be intimately related with the neuronal loss and 
inflammation observed in this pathology.  
Although AD can be considered a sporadic disease associated with the aging process, a 
small percentage of AD cases have been associated with specific gene mutations and/or 
duplications, emphasizing the importance of the deregulation of protein expression in this 
pathology. 
MicroRNAs are conserved small non-coding RNAs that control gene expression at the 
posttranscriptional level and are, thus, essential to ensure proper cellular function. Alzheimer’s 
disease profiling experiments have shown that several microRNAs are implicated in the regulation 
of key genes involved in the amyloidogenic pathway (such as APP, BACE1 and MAPT), suggesting 
that miRNA deregulation can contribute to the progression of this disease  
The present study aims to unravel the role of microRNAs as posttranscriptional regulators 
in AD, evaluating how single nucleotide polymorphisms (SNPs) present in the 3’UTR of two AD-
related genes (APP and ApoE) can influence miRNA binding and, consequently, APP and ApoE 
expression.  
Using a gene sequencing technique based on the Sanger method, we were able to identify 
and validate a heterozygous SNP in the 3’UTR region of the APP gene, which may contribute to AD 
onset and development. Our results suggest that the presence of this SNP can interfere with the 
binding of several miRNAs to the mRNA of APP, promoting APP upregulation and the consequent 
increase of Aβ deposition in the nervous tissue. In addition, using a luciferase-based assay, we 
were  able to provide evidence that miRNA-485-5p is capable of regulating APP expression at the 
posttranscriptional level, by binding to the 3’UTR of APP mRNA, thus validating APP as a direct 
target of this miRNA..  
Taken together, our results highlighted the effects of miRNA-related genetic variations in 
the etiopathology of AD and suggest that miRNA-485-5p can be a new and interesting therapeutic 
target for this disease. 
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Resumo 
A doença de Alzheimer é uma patologia neurodegenerativa grave, caracterizada pela 
acumulação extracelular de placas do péptido β-amilóide e por uma fosforilação excessiva da 
proteína Tau. Ambos estes factores aparentam estar intimamente relacionados com a perda 
neuronal e inflamação que são verificadas nesta doença. 
 Apesar de a doença de Alzheimer poder ser considerada uma doença esporádica, 
associada ao envelhecimento, uma pequena percentagem dos casos diagnosticados estão 
associados a mutações ou duplicações de genes específicos, dando ênfase à importância que a 
desregulação da expressão proteica pode desempenhar nesta patologia.  
Os microRNAs sao pequenos RNAs não codificantes que regulam a expressão génica ao 
nível pós-transcripcional, sendo assim fundamentais para o desempenho eficaz das funções 
celulares. 
Estudos do perfil de microRNAs, no contexto da doença de Alzheimer, permitiram 
indentificar vários microRNAs implicados na regulação de genes envolvidos no desencadeamento 
da cascata amiloidogénica (tais como os genes da APP, BACE1 e MAPT), reforçando a ideia de que 
os microRNAs podem contribuir para a progressão desta doença. 
O prsente estudo procura esclarecer o papel dos microRNAs como reguladores pós-
transcripcionais na doença de Alzheimer, avaliando de que forma a presença de polimorfismos na 
sequência de nucleótidos da região 3’UTR de dois genes implicados nesta doença (APP e ApoE) 
pode influenciar a ligação de microRNAs a esta região e, consequentemente, afectar a expressão 
destes mesmos genes. 
Usando uma técnica de sequenciação baseada no método de Sanger, identificámos e 
validámos a presença de um polimorfismo heterozigótico na região 3’UTR do gene da APP, que 
pode contribuir para incidência e desenvolvimento da doença de Alzheimer. Os nossos resultados 
sugerem que a presença deste polimorfismo pode interferir com a ligação de vários microRNAs ao 
RNA mensageiro da APP, promovendo assim a produção do peptídeo precursor amilóide e 
aumentando a deposição de placas senis no tecido nervoso. Através de um ensaio baseado na 
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expressão de luciferase, demonstrámos também que o microRNA-485-5p é capaz de regular a 
expressão da APP através da  ligação á região 3’UTR do RNA mensageiro, validando assim o RNA 
mensageiro desta proteína, validando-a assim como um alvo directo deste microRNA. 
Em conjunto, estes resultados realçam os efeitos que as variações genéticas relacionadas com 
os microRNAs podem causar na incidência e desenvolvimento da doença de Alzheimer e sugerem 
que o microRNA-485-5p pode providenciar um novo e interessante alvo terapêutico para esta 
doença. 
Palavras-chave: Peptídeo precursor amilóide, Apolipoproteína E, 3’UTR, 
Alzheimer 
 
 
1 
MiRNA contribution to APP metabolism and Aβ production in Alzheimer’s disease: 
Identification of new miRNA-related SNPs in the 3’UTR of human APP and APOE genes 
 
 
 
 
 
Introduction 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2 
MiRNA contribution to APP metabolism and Aβ production in Alzheimer’s disease: 
Identification of new miRNA-related SNPs in the 3’UTR of human APP and APOE genes 
1. Introduction 
 
With the current worldwide aging demography there is an increasing toll on health care costs 
and population’s life quality due to a higher incidence of age-related clinical conditions, such as 
dementia1,2. 
 Dementia is a clinical syndrome defined by the constant decline of an individual’s cognitive 
abilities such as memory, language, logic thinking and spatial orientation.  1,3. 
When a diagnosed case of dementia is coincident with abnormal accumulation in the brain of 
insoluble aggregates of both amyloid plaques (also known as senile plaques) and neurofibrillary 
tangles it is referred to as a case of Alzheimer’s Disease4 1. Alzheimer’s disease accounts for over 
60% of all cases of dementia worldwide. 1,5. However, the accumulation of this non-soluble protein 
aggregates can also be found in brains of patients suffering from other neurodegenerative 
diseases and even in patients without any history of neurological pathology. Therefore, by 
themselves, these structures cannot account for all the clinical symptoms of AD, suggesting the 
contribution of additional factors to the full development and establishment of the disease. 6,7 8 
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1.1 The multifactorial traits of Alzheimer’s disease 
1.1.1 Amyloid-beta peptides 
The so called “senile” plaques are composed mainly of amyloid-beta (Aβ) peptides, a 
typically 39–43 amino acid sequence derived from the sequential proteolytic processing of the 
APP. 7 9 In humans, APP exists in three major isoforms that are generated by alternative splicing. 
APP can be processed by α-secretase in a non-amyloidogenic pathway, generating a soluble 
peptide designated APPα, wich only contains thea C-terminal fragment of the Aβ peptide. 
Alternatively, in the amyloidogenic pathway, consecutive cleavage of APP by BACE1 and the γ-
secretase complex generates the soluble APPβ, Aβ peptide and the AICD which can be further 
cleaved by caspases (figure1). 10 
 
Figure 1. Schematic drawing of the Amyloid Precursor Protein (APP) and its processing pathways. In 
humans, APP exists in three major isoforms that are generated by alternative splicing (APP 695, App 751 and 
APP 770). APP can be processed by α-secretase in a non-amyloidogenic pathway, which generates soluble 
APPα (sAPPα ). Alternatively, in the amyloidogenic pathway, cleavage by the β-secretase BACE1 generates 
soluble APPβ (sAPP β), which is secreted, and a C-terminal fragment that is retained in the membrane. 
Subsequent cleavage of the C-terminal fragment by the γ-secretase complex generates Aβ and the APP 
intracellular domain (AICD) which can be further cleave d by caspases to produce a c31 fragment.10 
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Aβ peptides can be detected in the cerebrospinal fluid and often are present in 
conditioned media from various tissue cultures and several cell lines, suggesting that they are 
constantly produced and secreted 7. Since such secretion occurs in normal healthy individuals, the 
presence of Aβ by itself, in its soluble, unfibrillized state, is not meaningful of a pathologic 
condition9,11 12. 
Despite being the most famous molecular aspect of AD and having a well established 
presence in several amyloid systemic diseases, studies have also shown that Aβ plaque 
concentrations poorly correlates with the progression and severity of the symptoms in this 
pathology. Moreover, transgenic animals that develop widespread Aβ plaque deposition due to 
mutant APP overexpression, show only slight cognitive deficits 7 13. 
Neurons overburdened with intracellular Aβ peptides eventually undergo synaptic and 
dendritic degeneration, ultimately resulting in cellular lysis.  
Experimental evidence suggests that astroglial cells are able to phagocyte Aβ peptides in a 
process which may be ApoE dependent4. Once internalized, Aβ induces functional changes in 
astrocytes, which included spikes in the concentration of Ca2+ and mitochondrial depolarizaton, 
resulting in oxidative stress damage, as well as reversal of the glutamate uptake system which in 
turn results in additional glutamate release levels exacerbating neuronal damage 14 4.  
However, despite the ability of astrocytes to accumulate a substantial intracellular amount 
of Aβ, this process eventually leads to cellular death and culminates in the release of Aβ back to 
the extracellular space. 15 16 
With the increasing dispersal of cellular contents, the activity of released lysosomal 
enzymes leads to the formation of spherical deposition of cell residues in the form of plaques, the 
size of which is directly proportional to the type of the cell from which they were derived 15. 
In response to cellular death, both the smaller astrocytic plaques and the larger neuronal 
derived plaques are rapidly infiltrated by microglia and macrophages (most of which are believed 
to be derived from blood monocytes) 15 14. 
Once at the plaque core, microglia appears to concentrate the released Aβ and promote 
its fibrillogenesis within tiny, tube-like invaginations in the plasma membrane 15.  The mature 
amyloid fibrils could represent a cellular mechanism of detoxifying potentially harmful polypeptide 
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chains by sequestering them into insoluble and biologically inert materials. 13. Meanwhile, 
astrogliosis is also shown to prominently occur around amyloid plaques. This could be interpreted 
as a mechanism to prevent the amyloid plaques from establishing contact with neurons and 
generate a chain reaction effect from the peptide radial extracellular dispersion .15 14. 
Recently, the amyloid intermediates have been considered to be the true responsibles for 
AD pathology development and they also appear to be involved in several extra cerebral amyloid 
diseases like the lysozyme, transthyretin and amylin amyloidosis 13. 
In AD, the soluble Aβ monomers can form higher-order assemblies ranging from low-
molecular weight oligomers, like dimers and trimers, to mid range-molecular weight oligomers to 
protofibrils and fibrils that ultimately compose the plaques 17. 
Studies show that the Aβ dimmers, trimers and other higher order oligomers secreted by 
cultured neurons inhibit LTP and damage neuronal spines. Additional studies have also shown that 
Aβ dimmers, derived from human cerebrospinal fluid disrupt synaptic plasticity and inhibit 
hippocampal LTP in vivo 18. 
Multiple forms of Aβ oligomers appear to exist and co-exist in the brain tissue and are able 
to alter neuronal and cognitive function. Each of these forms may act on different receptors, 
activating either specific or unspecific signaling pathways and resulting in different consequences 
to neuronal synaptotoxicity and survival, with different effects at different times during the 
evolution of the disease. 17 Therefore, blocking the initial overproduction and accumulation of Aβ 
in neurons can be considered a promising target from a therapeutical standpoint. 
1.1.2 The neurofibrillary tangles 
NFTs are composed of paired helical filaments, which are structures made of abnormal 
hyperphosphorylated forms of the microtubule-associated protein Tau, presents a size between 
10nm and 20nm width with a half periodicity of 80 nm, and reaching an average of 300–600nm in 
length. 4 19 20 
The Tau protein is encoded by a single gene (MAPT) located on chromosome 17, although 
it is alternatively spliced to yield six major protein isoforms in the adult human brain. The 
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alternative splicing of exon 10 yields isoforms with either three or four repeated domains, referred 
to as 3R and 4R Tau, depending if exon 10 is absent or present, respectively.21 
Tauopathies can be distinguished based on the predominant tangle isoform. For instance, 
in AD both 3R and 4R tau accumulate in neurofibrillary tangles while in Pick’s disease only marked 
3R Tau can be found.21 
The Tau fibrillization pathway is thought to consist of at least three key steps. First, the 
microtubule binding function of Tau is neutralized so that Tau protein can accumulate in an 
assembly competent form at a specific intracellular location. Second, Tau molecules must self-
associate through their microtubule binding repeat regions to form the β-sheet enriched filaments 
observed in the brain. At last, the third step involves the nucleation of tau filament and formation 
of mature NFTs. Hyper phosphorylation can occur in all of these steps. 20 
High levels of NFTs block the transport of nutrients and other essential molecules 
throughout the cell, ultimately leading to neurite distrophism. The tangles form aggregates 
conjugated with ubiquitin, a property shared with other aggregating intraneuronal proteins, such 
as α-synuclein. 22 7 
In AD, the lesions seem to develop in a pattern fashion, which reflects the sequence, type 
and severity of cognitive decline and neuronal loss. Studies suggest that Tau fibrillization can be 
used as a marker for the disease, correlating with both cognitive decline and neurodegeneration. 
In transgenic animals, the presence of Tau revealed to be significant for Aβ to exert its toxic 
effects, thus reinforcing the significance of NFT’s in AD. 10 20 
To better understand the role of NFTs in this condition, triple-transgenic mice, referred to 
as 3xTg-AD, were developed as a model for AD. This model was developed by microinjecting the 
APPswe and TauP301L genes into single-cell embryos of PS1M146V KI mice. The 3xTg-AD mice 
progressively develop Aβ and Tau pathology with a temporal- and region-specific profile that 
closely mimics pathological development in the human AD brain 21. 
In this model, Aβ deposition develops before the tangle pathology. Whereas extracellular 
amyloid deposits manifest by six months of age, conformational changes of Tau are not apparent 
until approximately 10-12 months of age. Tau immunostaining reveals a hierarchal pattern to the 
Tau staining. The first marker to appear is MC1, followed by phophospecific markers, such as AT8 
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and AT180, and finally PHF-1. These results indicate that Tau undergoes conformational changes 
before becoming hyperphosphorylated. 21. 
Again, despite being the first hallmark to arise, Aβ initial deposition was shown to be 
insufficient to trigger the key aspects of AD, one of them being neuronal loss, pointing NFT’s as the 
likely responsible for the neurodegeneration and LTP deficits that occur in AD 21. 
1.1.3 ApoE 
ApoE is a glycoprotein synthesized as an 18 amino acid N terminal signal peptide that 
undergoes intracellular processing before being secreted in a 35 kDa mature form containing 299 
amino acids. It contains amphipathic α-helical domains that conformationally adapt, in a reversible 
manner, between a lipoprotein-bound and a lipid-free state and act as a ligand for the LDL 
receptor 23 24 25. 
The protein is encoded by a 3.6 kbp Gene, with 4 exons, located on chromosome 19 24. 
The physiological role of ApoE is exerted in lipoprotein particles, an assembly of both 
proteins and lipids that are responsible for the intracellular and extracellular trafficking of lipids. 
The cholesterol transport function of ApoE involves interaction with the cell surface receptor 
ABCA1 that promotes efflux of cellular cholesterol to the acceptor lipoproteins. ApoE also 
functions as a ligand in receptor-mediated endocytosis of apo E-containing lipoproteins, allowing 
them to bind and be internalized by receptors of the LDL receptor family wich are located on the 
cell surface of neurons. 24 26 27 
 
There are lipoproteins of different size classes in plasma, mainly synthetized by the liver 
and gut. Plasma ApoE, in particular, originates predominantly from the liver but is expressed as 
well in a wide variety of other tissues, including the brain, spleen, lungs, ovary and kidney24 28. 
Exchange between liver and brain-derived ApoE and ApoE-containing lipoproteins does not take 
place due to the blood-brain barrier, meaning that all the brain ApoE must be synthetized locally. 
29 
In the CNS, ApoE it is the most abundantly produced apolipoprotein and is predominantly 
expressed by astrocytes, but also microglia, in nascent high-density lipoprotein (HDL)-like particles. 
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In the occurrence of excitotoxic injury, ApoE is also found to be expressed in neurons of the 
hippocampus and cortex 28 26. 
Cholesterol depletion, or a lack of cholesterol delivery, causes synaptic and dendritic spine 
degeneration and results in failed neurotransmission and decreased synaptic plasticity culminating 
in neuronal cell damage and eventually cellular death. On these conditions, ApoE is up-regulated 
for clearance and redistribution of cholesterol the lipid debris 24. 
Since it has been shown that cholesterol-containing ApoE lipoproteins are required for 
synapse formation, in vitro, via a mechanism that is dependent upon functional ApoE receptors, 
which are up-regulated in regenerating peripheral nerves, it is suggested that the importance of 
ApoE is not limited to cholesterol homeostasis, but is also related to neuronal plasticity, neurite 
growth and synaptogenesis 24 28 26. 
Humans have 3 common ApoE isoforms that result in single aminoacid substitutions 
trough SNPs: ApoE2, ApoE3 and ApoE4. Each one differ from the others only at the 112th and/or 
158th aminoacids. For instance, ApoE3 contains a cysteine at position 112 and an arginine at 158 
while ApoE2 contains cysteines at positions 112 and 158 and ApoE4 contains arginines in both 
sites 24 28. 
The high allelic frequency of ApoE isoform E3 in the human population and the lack of 
strong association of this isoform with a human disease phenotype, points ApoE3 as the human 
“wild-type”. Curiously, ApoE4 appears to be the ancestral form, since the Arg residues at sequence 
positions 112 and 158 are strongly conserved across almost all animal species possessing ApoE 30 
24. 
 
Each one of this isoforms bears distinct structural and functional properties as discriminated in 
Table 1 24 28 23. 
 
9 
MiRNA contribution to APP metabolism and Aβ production in Alzheimer’s disease: 
Identification of new miRNA-related SNPs in the 3’UTR of human APP and APOE genes 
 
The LDL receptor binding activity of ApoE2 is approximately 1% of that of the parent 
isoform, while ApoE3 and ApoE4 bind to LDL receptors with similarly high affinity. As a result, 
ApoE2 is associated with type III hyperlipoproteinemia, a lipid disorder characterized by increased 
plasma levels of cholesterol and triglycerides 23. 
The most pronounced pathology attributable to ApoE polymorphism in humans is the 
association of ApoE4 with neurodegenerative diseases, in particular with Alzheimer’s disease 24. 
 
ApoE4 is a major risk factor for AD. Those who inherit one ApoEε4 gene not only possess 
increased risk of developing AD but also an increased chance of pathology onset at an earlier age, 
in comparison to those who inherit the ε2 or ε3 forms of the ApoE gene. The risk of developing AD 
is proportional to the genetic amount of the ε4 allele, meaning that individuals who are 
homozigotic for the ApoEε4 gene have an even higher chance of developing AD 1. 
The plasma concentration of ApoE in ε4 homozygous human carriers is lower than that 
observed in individuals possessing two ε3 alleles. Furthermore, such individuals manifest elevated 
plasma cholesterol and LDL levels. More importantly, the inheritance of ApoE4 is correlated with 
cerebral amyloid angiopathy, tauopathies and dementia, not only in AD but also in Parkinson's 
disease and multiple sclerosis1 24. 
It is noteworthy that being a susceptibility gene means that its sole presence is neither 
necessary nor sufficient for the development of Alzheimer’s disease. Moreover, the full influential 
aspects of ApoE haplotypes upon Aβ and tau are still to be determined 1. There seems to exist an 
isoform-dependent propensity (ε 4> ε 3> ε 2) for Aβ to be deposited as cerebral amyloid plaques 
in experimental animals and in humans. ApoE4 carriers have also shown increased cerebral 
amyloid deposition in comparison with noncarriers 12  31. 
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The ApoE genotype also seems to affect the lipidation states of apolipoproteins and Aβ 
peptides in the cerebrospinal fluid 32. 
Despite having a reportedly higher lipid binding affinity than its counterparts, the ApoE4 
physiological ability to promote cholesterol efflux is remarkably lower than that of ApoE3 and 
ApoE2, presumably due to the structurally limited interactions of ApoE4 with ABCA1 receptors28 24. 
ApoE degradation is preferentially conducted by astrocytes, with lipidated ApoE being less 
susceptible to proteolysis than lipid-free ApoE. This may explain the genotype-dependent ApoE 
total levels in brain and CSF, when the ε4 allelle shows the lowest protein levels, followed by ε3 
and with ε2 correlating with the highest protein levels 24. 
Since apoE4 fragments have been co-localized with amyloid deposits in plaques and also in 
neurofibrillary tangles in the brains of AD patients, the apoE genotype correlation in both protein 
levels and propensity to Aβ plaque formation may be suggestive that apoE4 digestion products 
contribute to amyloid plaque formation and overall AD pathology 26. Studies have shown that Aβ 
and delipidated apoE4 promote fibril formation more rapidly and with higher density in 
comparison to other apoE isoforms. It is possible that degradation by-products of delipidated 
ApoE can somehow act as a catalyst in Aβ plaque formation 24. 
Another factor that influences the amount of Aβ deposited is the extent of lipidation of 
the ApoE protein. Lipid-free and lipid-bound apo E exists in different conformations and the 
affinity of lipidated apo E for soluble Aβ is greater than that of poorly-lipidated ApoE. 26 Lipidated 
ApoE seems to facilitate the cellular uptake of Aβ trough the endocytosis of a complex of ApoE-
containing lipoprotein particles bound to Aβ. Furthermore, ApoE has been shown to directly 
enhance both the degradation of Aβ within microglial cells and the ability of astrocytes to clear 
diffuse Aβ deposits (figure2) 28.  
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Figure 2. Schematic model of Aβ peptide and ApoE interaction in the CNS. When ApoE is more lipidated, it presents 
higher propensity for Aβ binding, which facilitates its clearance and degradation. When ApoE is less lipidated, which 
occurs when the ApoE4 isoform is present, it is less able to bind Aβ. When Aβ binds to carrier proteins, such as ApoE, it is 
more likely to be cleared through enzymatic degradation processes or cross the blood-brain barrier (BBB). However, 
when Aβ is not bound to proteins, it is more prone to oligomerization. Aβ oligomers are toxic to synapses and neurons 
32
. 
The cellular internalization of the lipoprotein-Aβ complex is mediated by the LDL receptor 
family by receptor-mediated endocytosis. Therefore, since it was shown that Aβ can be 
internalized in the absence of ApoE, it is possible that the Aβ will undergo different endocitic 
routes depending on the activated internalization method 33. 
Lipoprotein-Aβ complexes also contribute to Aβ removal from the brain to the systemic 
circulation by both endocitic and receptor-mediated transport across the blood brain barrier, 
allowing for both hepatic and renal Aβ systemic clearance 34. 
Regarding tau, several studies of ApoE overexpression in mice were able to correlate the 
ApoE4 isoform with increasing levels of hyperphosphorylated tau in neurons. Since neuronal ApoE 
expression only seems to occur as a damage induced response, the physiological significance of 
these studies sugest that the ApoE influence, upon the thauopathic profile of AD, to be dependent 
of already established neuronal damage. 35,36 At the molecular level, ApoE interaction with LDL 
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receptors was shown to inhibit several tau kinases like P35, P-GSK3β and CDK5, effectively 
resulting in lower tau phosphorylation levels 37. 
Despite the relationship between ApoE and tau phosphorylation, human CSF tau and 
phosphorylated tau levels were shown to have no correlation with ApoE haplotypes, suggesting 
that ApoE4 may influence AD onset mainly via an Aβ related mechanisms  12 38. 
Only about one percent of the AD cases are known to be caused by rare genetic 
mutations. These mutations can involve autosomal dominant gene mutations and/or duplications 
in the locus for the amyloid precursor peptide (APP) on chromosome 21, for the presenilin 1 
protein on chromosome 14, and for the presenilin 2 protein on chromosome 14,22. Inheriting any of 
these genetic mutations guarantees that an individual will develop AD in a clinically 
indistinguishable pattern from the sporadic form. In such individuals, the disease tends to develop 
before the age of 65, sometimes in individuals as young as 30. People inheriting this mutations or 
that possess more than one close relative already diagnosed with AD are said to have the 
“familial” form of AD and account for about 5% of all documented AD cases22 39. 
The remaining  95%  of  all  cases  of  AD  are  considered sporadic  forms  of  the  disease, 
from which over  60%  are not associated with ApoE genotype, suggesting that other genetic  or 
maybe  environmental  factors  may  contribute  to this disease onset. 
Taken together, both the accumulation of insoluble protein aggregates and gene 
duplications verified in AD emphasize the importance of protein expression deregulation in this 
pathology. 
1.2 MicroRNAs 
MiRNAs are small non-coding RNAs that control gene expression at the posttranscriptional 
level. On a neurobiological context, they are essential for neuronal function and survival 40. 
These short (approximately 21-23 nucleotides) conserved non-protein-coding RNAs are 
transcribed from the genome 40. In mammals, more than one thousand miRNAs have been 
identified and approximately one-third of miRNA genes are located within introns of protein-
coding messenger RNAs (mRNAs), while the remaining are intergenic.  After transcription, miRNA 
precursors are cleaved in the cytoplasm by the RNase Dicer to produce small double-stranded 
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nonprotein-coding RNAs. Successive processing of the miRNA precursor molecule generates a 
single-stranded miRNA (mature miRNA) 40 41. 
Mature miRNAs latter function as part of the RNA-induced silencing complex (RISC), which 
targets specific mRNA transcripts preferentially located in the 3’UTR of genes. Binding of the 
miRNA to its target leads to translation inhibition and/or mRNA degradation of the target 40 42,43 43 
41. 
Despite having their maturation processes and regulatory functions taking place in the 
cytoplasm, miRNAs were also detected in the circulating plasma. Even with the high concentration 
of RNAses, circulating miRNAs still show significant stability since they are believed be 
incapsulated in lipid structures known as exossomes 44,45. 
A miRNA “family” is defined as a group of miRNAs sharing the same seed region (sequence 
between the 2nd and 8th nucleotide of the miRNA) and that in most, but not all, cases might target 
the same gene 40. 
It is predicted that 25 to 70% of all protein-coding genes can be regulated by miRNAs, 
depending on the developmental, cellular, and/or physiological context. Moreover, a single miRNA 
can target up to several hundred genes, thus potentially regulating multiple biological pathways, 
including those implicated in neuronal survival 40 42. 
This potential multiplicity of gene targeting makes assessing and proving that a specific 
gene or pathway is indeed a target of a particular miRNA an elusive and nontrivial task. A major 
disadvantage in miRNA research is the difficulty in validating putative target mRNAs predicted for 
a specific miRNA. There are available variety of online algorithms that utilize different approaches 
to predict miRNA–mRNA interactions, but the predicted targets for each miRNA in each database 
might be dissimilar, largely non-overlapping and often exclude many experimentally proven and 
validated targets 46. 
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1.2.1 MiRNAs in Alzheimer’s disease. 
Results from recent profiling experiments in humans suggest that a number of specific 
miRNAs are misregulated in disease conditions, several of which have been implicated in the 
regulation of key genes involved in AD, including APP, BACE1 and MAPT. Moreover, rare disease-
specific polymorphisms have been identified in known and putative miRNA target sites of APP and 
BACE1 genes 40. 
Several miRNAs are expressed specifically in neurons, where some are proposed to 
function in neuronal activities, such as neurite outgrowth and synapse formation. In fact, there are 
some interesting parallels that can be established between a Dicer-deficient brain and an AD 
brain. A Dicer-deficient brain lacks functional miRNAs due to the absence of the Dicer enzyme, 
which cleaves miRNA’s precursors into single-stranded functional miRNAs (mature miRNAS). 
Neuronal Dicer cKO mice develop progressive neurodegeneration, presenting reduced brain size, 
enlarged ventricles, neuroinflammation, apoptosis (in some cases), as well as impaired dendritic 
branching and spine length. In addition, neuronal Dicer cKO mice exhibit AD-like 
hyperphosphorylation of endogenous Tau, which is not observed in non-transgenic mice. Such 
results further reinforce the idea of AD as a miRNA dysfunctional disease 41,47. 
Specific loss of Dicer in oligodendrocytes results in axonal degeneration accompanied by 
abnormal axonal transport and endogenous APP accumulation. This model also displays signs of 
oxidative stress, and, taken together, these results point out the importance of Dicer and miRNAs 
in maintaining neuronal function 47. 
The impact of miRNA modulation of APP metabolism and Aβ production seems to be 
intimately involved and of major relevance in AD development (Figure 3). Therefore, aspects 
inherent to AD that compromise miRNA function may not be only restricted to variations in miRNA 
levels 42. 
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Figure 3. Schematic representation of the miRNA network surrounding APP. Both upstream and downstream 
components directly or indirectly affect APP processing and Aβ metabolism 
42
. 
The hypothesis of a secondary factor, besides miRNA transcription levels 
influencing miRNA, lies in AD-specific genetic mutations in the 3’UTRs of APP,  BACE1 and 
ApoE genes, which can either abolish existing miRNA binding sites or create new 
illegitimate miRNA binding sites that could contribute significantly an increased risk of 
developing this neurodegenerative disorder. 42. 
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1.2.2 3’UTR SNPs and their effects on miRNA function in AD 
The known AD specific APP variants that arise from such mutations are T171C, A454G and 
A833C (figure 4) 42. 
When assessing the effects of miRNAs in the regulation of the several variants of APP, it 
was observed that MiRNA-147 was significantly affected by the T171C mutation when compared 
to the wild-type construct, showing a propension to inhibit APP expression in the presence of the 
T171C SNP. On the other hand, miRNA-20a, but not miRNA-17, was affected by the A454G 
mutation, further decreasing the expression of APP in the presence of A454G SNP 42. 
 
Figure 4.  Schematic representation of base pair matching between miRNAs and the 3 ’UTR of human APP. The seed 
region of the miRNAs is indicated. The red bases represents the SNPs T171C (upper panel) or A454G (lower panel). 
Adapted from 
42
. 
For miRNA-147, the effect may be explained by the fact that T171C is located immediately 
adjacent to the miR-147 seed region binding site, therefore directly inhibiting miRNA binding. This 
effect can also be theoretically explained by the increase in the required binding energy between 
miR-147 and the 3’UTR of APP, which makes the binding less favourable, therefore decreasing the 
ability of this miRNA to modulate APP levels 42. 
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Such results show that polymorphisms located in the 3 ’UTR region of APP may affect the 
expression of this protein. More importantly, these polymorphisms may constitute a new aspect 
to consider when developing new diagnostic tools and miRNA dependant therapies42. 
 Aiming at better comprehending the genetic features of AD pathogenesis that contribute 
to miRNA dysfunction, in the context of this disease, we propose a two way approach, based on 
the identification of unknown SNPs in the 3’UTR of the APP and APOE genes of both AD patients 
and healthy controls and on the evaluation of the ability of specific miRNAs to modulate APP 
production in neuronal cells. 
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2. Objectives  
 
This study aims to establish a SNP profile of the 3’UTR of APP and ApoE genes, in 
AD patients, in order to evaluate their significance as modifiers of miRNA function and 
their contribution to AD onset and severity. 
The specific goals of the study are: 
 To identify SNPs in the 3’UTRs of  the APP and ApoE genes, and evaluate the 
significance of this SNPs as modifiers of miRNA function and AD development; 
 To perform a validation study on the miRNA binding strength and APP modulation 
capacity of miRNAs predicted to target the 3’UTR of the human APP gene, aiming 
at identifying miRNAs capable of decreasing APP production in a therapeutic 
setting. 
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Materials and Methods 
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3. Materials and Methods 
3.1 Materials 
NZY Blood gDNA isolation kit, NZYgelpure PCR purification kit,NZYTaq DNA polymerase, 
dNTPs, and MgCl2 were purchased from NZYtech (NZYtech, Portugal). The custom designed 
primers were obtained from Alfagene (Alfagene, Portugal) GenomeLab™ DTCS Quick Start Kit was 
obtained from IZASA. Plasmids for miRNA-485-5p and APP 3’UTR reporter expression were 
purchased from OriGene.  The LipofectamineTM LX Transfection Reagent was purchased from 
Invitrogen. 
3.2 Subject selection and sampling 
All participants in this study were recruited at the Dementia Clinic from the University of 
Coimbra Hospital Center and were subjected to a detailed clinical and psychiatric examination. 
According to their clinical status, the subjects were divided into 3 groups: healthy controls 
(group 1, n=12), AD patients (group 3, n=25) and patients with MCI (group 2, n=18). For the 
establishment of the control groups only individuals with no prior history of neurological or 
psychiatric diseases were selected. 
In individuals diagnosed with AD or MCI, the diagnose was further confirmed through 
imaging studies, measurement of hippocampus atrophy, ApoE genotyping and AD biomarker 
profiling, including quantification of Aβ42, total tau and phosphorylated tau levels in the 
cerebrospinal fluid. 
A 20 mL blood sample was collected from each subject into sterile EDTA coated tubes, 
according to a protocol approved by the ethics committee of the hospital and after receiving a 
written consent from the study participants or their next of kin. 
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3.3 DNA storage and extraction from blood samples 
From each 20 mL sample, 200 µL of blood were withdrawn for storage into genomic DNA 
cards (Nucleocard, Macherey-Nagel) and 400 µL were separated for DNA extraction. 
DNA extraction was performed using the NZY Blood gDNA isolation kit.  Briefly, 225 µL of a 
proteinase K-containing lysis buffer was added to a 200µL blood sample, vortexed and incubated 
for 15 minutes at 56°C. In order to provide proper DNA binding conditions to the silica-based 
purification columns, a volume of 210 µL of ethanol was added to the sample, followed by 
homogenization trough vortex. The resulting solution was applied into the purification columns 
and underwent a short centrifugation of 1 minute at 11.000 g.  Two follow-up centrifugations with 
washing buffers NW1 and NW2, also performed at 11.000 g during 1 minute, minimized the non-
specific interactions of other molecules with the purification column. 
Finally, after drying the column through a 2 minutes long 11.000 g centrifugation, the 
purified DNA was eluted by incubating the column with 50µL of sterile water for 1 minute followed 
by another centrifugation of 2 minutes at 11.000 g.   
The purified DNA samples were quantified using a NanoDrop device and stored at -20°C. 
The purity of the samples was evaluated taking into consideration their 260nm/280 nm and 
260/230 nm ratios. 
 
3.4 Primer design  
NCBI’s primer blast tool combines the primer designing capabilities of the Primer3 
software with BLAST and global alignment algorithms, allowing the custom design of PCR primers 
according to any available nucleotide sequence databases.  
The 3’UTR sequences of both APP and APOE were obtained through the Ensembl 
(ensembl.org) and MiRNA.org (miRNA.org) databases and cross-referenced with GRCh37.p10 
genomic build trough NCBI (ncbi.nlm.nih.gov).  
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Figure 5. NCBI interface of the 3’UTR regions of both the APP and ApoE genes and neighboring sequences. The APP 
3’UTR  is highlighted in black and the ApoE 3’UTR is highlighted in blue. Each of the green bars in the APP gene is 
representative of a distinct APP isoform.  
 
Primer locations were aimed at the 3’ and 5’ flanking sequences of the desired templates 
in order to comprise the entirety of the 3’UTR sequence upon amplification and sequencing. 
Due to the extent of the APP’s 3’UTR sequence (1119 bp), two additional primers were 
designed in order to decrease possible sequencing errors. As such, the APP 3 UTR was sequenced 
and analyzed through 4 contiguous sequences. 
Only primers that didn’t exhibited any predictable dimerization or hairpin structures were 
considered viable for optimization. The prediction of secondary structures was performed trough 
OlogoCalc (basic.northwestern.edu/biotools/OligoCalc) 
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3.5 APP and ApoE 3’UTR DNA amplification 
The 3’UTRs of both the APP and ApoE genes  were amplified from the DNA isolated from 
the blood of each study participant using PCR. 
A standard master mix template (table 2) and custom PCR conditions, using a gradient of 
annealing temperatures, were used to optimize the specificity of the designed primers and final 
product yield. 
For each reaction, 22,5 µL of Master Mix were added to 2,5 µL of DNA at a 10 ng/µL 
concentration.  
Table 2.Standard master mix template used in the PCRs 
 
The amplification conditions used for each 3’UTR are discriminated in Tables 3 and 4 
Table 3. Amplification conditions used for the amplification of the 3’UTR of APP. 
APP 
Cycle step temperature time cycles 
Initial denaturation 98°C 1min 1 
Denaturation 98°C 10s 
35 
 
Annealing 61°C 10s 
Extension 78°C 1min 20s 
Final extension 78°C 5min 1 
Storage 4°C ad infinitum 
 
 
Reaction buffer 10 x 2,5 µL
dNTP mix 5 mM 200 µM 1 µL
Primer FW 10 µM 0,5 µM 1,25 µL
10 µM 0,5 µM 1,25 µL
NZYTaq 5  U/µl 0,04 U/µl 0,2 µL
MgCl2 50 mM 1,5 mM 0,75 µL
Nuclease-free water 15,55 µL
Master mix Stock Desired concentration
Primer RE
-
reaction volume
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Table 4. Amplification conditions used for the amplification of the 3’UTR of ApoE. 
ApoE 
Cycle step temperature time cycles 
Initial denaturation 98°C 1min 1 
Denaturation 98°C 10s 
35 
 
Annealing 59°C 10s 
Extension 78°C 20s 
Final extension 78°C 5min 1 
Storage 4°C ad infinitum 
 
The resulting PCR products were confirmed by agarose gel electrophoresis, using a 1,5% 
weight/weight agarose gel stained with greensafe. A reaction tube containing 25µL of Master Mix 
alone was processed alongside each sample batch to act as negative control. NZYtech’s NZY ladder 
III was used as molecular weight marker for relative comparison in all agarose gels. The resulting 
bands were visualized by exposing the agarose gel to UV light. 
 
3.6 Purification of PCR Products 
The PCR reactions were purified using the NZY Gelpure kit (NZYTech) 
One hundred microliters of Binding Buffer were added to each PCR product and the 
resulting volume was transferred to a purification column. The Binding Buffer contains guanidine 
tiocianate, Tris-HCl and ethanol which allow DNA binding to the silica-based column. A 1 minute 
centrifugation at 14.000 rpm was performed, followed by the addition of 600 µL of wash solution, 
to remove salts, dNTPs and enzymes, and 2 consecutive 1 minute, 14.000 rpm centrifugations. 
After changing the column to a new 1,5ml eppendorf, the DNA was eluted by adding 50µL 
of Elution Buffer (10mM Tris-HCl, pH 8,5) and performing a final 14.000 rpm centrifugation during 
1 minute. 
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3.7 Sequencing Reaction 
The sequencing reactions were performed with the GenomeLabTM Dye Terminator Cycle 
Sequencing using the Quick Start kit, based on the Sanger method. The technique is based on the 
incorporation of fluorescently-labeled NTPs during the DNA chain synthesis, by a DNA polymerase. 
Each type of ddNTPs contains a different fluorochrome and during the sequencing reaction the 
labeled ddNTPs are incorporated in the 3’ end of the forming DNA strand, leading to the 
termination of the strand’s elongation due to the lack of a 3’-OH functional group. Therefore, the 
end result is a group of variable sized DNA sequences, each one terminating in a distinguishable 
fluorescent nucleotide. Briefly, each reaction tube consisted in 3 µL of DTCS Quick Start Master 
Mix, 1 µL of the desired primer (10 pmol/µL), 2 µL of purified PCR product (this volume could vary 
to a range of 0,5 µL – 10 µL depending on the PCR product’s relative concentration) adjusting up to 
a final total volume of 20 µL with dH2O. 
The sequencing program consisted in 30 cycles, with each cycle presenting 3 steps, 
followed by holding at 4°C. The first step was a denaturation step at 90°C for 20 seconds, in order 
to split the DNA double helix into single nucleotide chains, followed by the annealing step at 50°C 
during 20 seconds and finally a 4 minute extension step at 60°C. Resulting products were stored at 
-20°C or immediately purified. 
3.8 Purification of Sequencing Products 
A mixture of 62,5µL of ethanol 95%, 3µL of NaOAc pH 4,6 and 14,5 µL of ddH2O was added 
to each sample on a 96-well PCR plate. The plate was then sealed with Parafilm and stored at 20°C 
for 10 minutes. 
Three consecutive centrifugations were then performed at 5.700rpm and 4°C, during 30, 
10 and 5 minutes, respectively. Between each of the centrifugations, the supernatant was 
discarded and 200 µl of cold EtOh 70% (-20°C) were added to each well. 
The sample plate was then inverted over adsorbent paper and underwent one final 10 
second pulse at 700rpm to remove any remaining ethanol. 
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The pellets were then ressuspended on 25µL of formamide by vortex. In order to minimize 
evaporation a drop of mineral oil was added before loading the samples on the sequencer. 
3.9 3’UTR sequence reading and bioinformatic alignment of the 
sequencing products 
The sequence reading was performed on a Beckman Coulter’s CEQ 8000 Genetic Analysis 
System automatic sequencer. Briefly, the labeled DNA fragments underwent denaturation and 
were separated by capillary electrophoresis. Base calling was achieved by laser-induced 
fluorescence in four spectral channels, each one targeting a respective ddNTP fluorochrome. 
All the produced sequence read files were exported as a chromatogram and further 
analyzed on the SEQUENCHERtm software from Gene Codes Corporation. 
The control group sequencing reads were directly compared with the APP and ApoE 3’UTR 
sequences, present in the NCBI and ENSEMBLE databases, and were further used as reference 
sequences for direct comparison with the AD and MCI study group’s sequences.   
Whenever an occurrence of two overlapping peaks was identified on the chromatogram of 
the sequencing product, new PCR and sequencing reactions were performed in order to confirm 
and validate the result as a heterozygous SNP. 
SNPs were evaluated  to  detect  the  deletion  of  predicted  miRNA  binding  sites  or the 
appearance of new ones using information collected from the miRNA.org, miRwalk and Diana-
microT databases 
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3.10 Plasmid constructs  
The miRNA-485-5p expression plasmid contains the pre-miRNA nucleotide sequence with 
a 300 nts up- and down-stream flaking sequence (to ensure proper miRNA expression and 
maturation) cloned into a pCMV-MIR Vector via SgfI and MluI restriction sites.  
 Figure 6. pCMV-MIR vertor map 
The APP 3’UTR reporter clone consists in a firefly luciferase expressing vector with the APP 
3’UTR sequence inserted into the plasmid after the stop codon of the luciferase. The transcript 
level can be therefore regulated by its interaction with miRNAs. 
 Figure 7. pMir-Target vector map 
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3.11 Plasmid DNA amplification 
For plasmid amplification, a diluted stock of each plasmid was prepared at a concentration 
of 2,5 ng/µL. 
The transformation of competent E.Coli cells was performed through a heat-shock 
protocol. Briefly, 2 µL of the diluted stock of each plasmid were added to 50 µL of bacterial 
suspension and kept on ice for 20 minutes, followed by a 30 second immersion on a 42°C bath and 
a second step of 2 minutes in ice. 
After the transformation procedure, the bacteria were ressuspended in 350 µL of SOC 
medium and left incubating for 1 hour at 37°C and 220 rpm. 
After incubation, 100 µL of transformed bacteria were plated on LB-Agar plates with 
Kanamycin (25µg/mL) and left incubating at 37°C for 16 hours. 
For each plasmid, 3 individualized bacterial colonies were selected and inoculated 
separately in 8ml of LB-Kanamycin (25µg/mL), before undergoing a 16 hour long growth at 37°C 
and 220rpm. 
A second 16 hour long growth at 37°C, was performed after separately transferring 1,5ml 
from each previous inoculation into 650 ml of LB-Kanamycin (25µg/mL), this time at 180 rpm. 
3.12 Plasmid DNA purification 
Plasmid purification was performed using the Nucleobond® Xtra Maxi Plus kit (Macherey-
Nagel) and following the guidelines of the manufacturer. 
The transformed bacteria were initially harvested by centrifugation at 6.000 g for 10 
minutes at 4°C. 
The pellet was ressuspended in 24 mL of ressuspension buffer, containing RNase A, before 
adding 24 mL of lysis buffer. The mixture was gently homogenized and left at room temperature 
for 5 minutes. A volume of 24 ml of Neutralization buffer was then added, followed by a 10 minute 
centrifugation at 5000 g. 
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Meanwhile, the purification column was prepared by adding 25 ml of equilibration buffer. 
Once the column emptied, the supernatant was loaded, followed by the addition of 15 mL of 
equilibration buffer. 
The column filter was then removed and washed. Elution was performed by adding 15mL 
of Elution buffer. 
Desalting of the plasmid solution was performed by precipitating the resulting sample with 
0,7 volumes of room temperature isopropanol and loading it onto a NucleoBond® Finalizer 
membrane by means of a syringe. After a washing step with ethanol and drying of the membrane, 
the pure DNA was eluted with 800µ of TRIS Buffer. 
3.13 Cell culture and transfection 
HEK293T cells were thawed in a 37°C water bath, transferred to a 15 mL falcon tube 
containing 10mL of DMEM and centrifuged at 500g for 5 minutes. After removing the supernatant, 
the cells were ressuspended in 20mL of DMEM and transferred to a 75 cm2 cell culture flask. 
Cells were maintained at a maximum of 90% confluence at 37°C, in a 5% CO2 atmosphere.  
Cell dilution was performed by removing the growth medium, washing with 3 mL of PBS and then 
adding 2 mL of dissociation medium. After cell detachment, 6 mL of DMEM were added to the 
flask, before transferring the cell suspention to a 15 mL falcon tube (when unattended for longer 
than 48 hours 10 mL of DMEM were used instead to further dilute the cell suspension). 
For each new flask, 1mL of the cell suspension was plated and 19 mL of DMEM were 
added, proceeding with another incubation period at 37°C and 5% CO2. 
For the miRNA validation experiments, the cells were detached, as previously described, 
counted and plated on 24-well multiwell plates at a density of 1.200.000 cells/well in a final 
volume of 500uL.  The cells were maintained in these conditions for 24 hours until the beginning 
of the transfection procedure. Before transfection, cells were washed and the medium was 
replaced with 300µl of Optimem. 
Lipoplexes were prepared by combining, the miRNA-485-5p expression plasmid and the APP 3’UTR 
reporter clone plasmid with the Lipofectamine™ LX Transfection Reagent for 30 min at room 
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temperature in OPTIMEM. In parallel, control lipoplexes were prepared by combining the APP 
3’UTR reporter clone plasmid with a GFP expressing plasmid and the same transfection reagent. 
The different lipoplex formulations were then added to the plated cells aiming at a 
concentration of 1µg of each plasmid/well in a final volume of 500 µL. 
After 4 hours of incubation, the cells were washed and the transfection medium was 
replaced with DMEM. Cells were then further incubated for 48 hours. At this point, the growth 
medium was replaced by the luciferase lysis buffer and the plates were stored at -80°C until the 
luciferase activity could be quantified in each sample. 
3.14 Luciferase assay 
The cells were thawed in ice and gently scraped from the plate. The content of each well 
was transferred to a separate eppendorf and centrifuged at 14000 rpm for 5 minutes at 4°C. 
Fifty microliters of each supernatant were transferred to an opaque 96 well white plate. 
The bioluminescent reaction was performed and luciferase activity was measured in a 
luminometer. Briefly, 100 µL of reading solution (containing ATP) and 100 µL of luciferin (pH 8) 
were added to each well in a 5 second injection. The plate was then shacked for 1 second and the 
luminescence levels were recorded during a 10 second interval. The luminescence values were 
expressed as counts per second (CPS). 
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4. Results 
4.1 Primer optimization and 3’UTR amplification trough PCR 
4.1.1 APP 3’UTR amplification 
The parameters used in NCBI’s primer blast search tool for the App 3’UTR amplification 
resulted in 3 primer pairs. 
One of the selected primer pairs was designed to allow the full amplification of the APP 
3’UTR, and was designated as Primer pair 1, consisting in the primers Fw1 and Re1. The other two 
primer pairs (Primer pair 2 and Primer pair 3) were designated to amplify smaller, but contiguous 
sequences of the 3’UTR. 
 
Figure 8. Primer sequences used in the amplification and sequencing of the 3’UTR of the APP gene. 
Optimization of the amplification conditions was performed through several PCRs with 
annealing temperatures ranging from 49°C to 67°C and using a purified DNA sample from one of 
the control subjects. It was possible to observe that specific sequence amplification occurred for 
the primer pair 3 across all temperatures, although with a rather inconsistent yield, and for primer 
pair 2 up to 63°C. 
 
34 
MiRNA contribution to APP metabolism and Aβ production in Alzheimer’s disease: 
Identification of new miRNA-related SNPs in the 3’UTR of human APP and APOE genes 
 
Figure 9. Representative image of the resulting bands obtained from the optimization of the APP primer pair 2 and 
APP primer pair 3 at the different annealing temperatures. 
 
Figure 10. Representative image of the resulting bands obtained from the optimization of the APP primer pair 2 and 
APP primer pair 3 at the different annealing temperatures. 
The ideal conditions for the complete App 3’UTR amplification were also tested trough 
annealing temperature gradient. The PCR was performed using Primer pair 1 in a temperature 
range from 57°C to 61°C and using DNA samples from 4 study subjects, in order to assess any 
subject related influence on the final reaction yield and primer specificity . 
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Figure 11. Representative  image of the resulting bands obtained from the optimization of the APP primer pair 1 
product  in different patient samples at annealing temperatures of 57˚C, 59˚C and 61˚C. 
No amplification could be observed at 57°C in subject C14 and at 59°C in subject C10. All 
the other condition resulted in a single band. Taken these results in consideration, all subsequent 
3’UTR amplifications were performed with at 61°C annealing temperature using primer pair 1 and 
exhibited product specificity with similar yield. 
 
Figure 12. Representative image of the resulting bands obtained from amplification of the 3’UTR of the APP gene in 15 
different samples. The bands result from the PCR products obtained by using APP primer pair 1 and an annealing 
temperature of 61°C. 
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4.1.2 ApoE 3’UTR amplification 
In what concerns ApoE amplification, NCBI’s primer blast search provided 4 primer pairs. 
The PCR conditions for amplification were optimized for each primer using a single sample and a 
temperature gradient in the annealing step. The temperature gradient ranged from 57°C to 61°C in 
intervals of 2°C. 
 
 
Figure 13. Primer sequences tested in the amplification and sequencing of the 3’UTR of the ApoE gene. 
The resulting PCR products were analysed trough agarose gel electrophoresis. No 
amplification could be observed using primer pair 1,2 and 4. Primer pair 3 exhibited specific 
amplification across the entire temperature range, providing the highest yield at 59°C and was, 
therefore, selected to perform  ApoE 3’UTR PCR reactions at this annealing temperature for a set 
of 13 samples. 
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In this experiment, nonspecific amplification was detected in some samples by the 
presence of an unexpected band with approximately 700 bp.  
 
Figure 14. Representative image of the resulting bands obtained from the amplification of the 3’UTR of the ApoE gene 
in 13 samples, using ApoE primer pair 3 and an annealing temperature of 59°C. 
In order to avoid this problem, a new annealing temperature gradient was performed 
ranging from 59°C to 69°C. 
Figure 14. Representative image of the 
resulting bands obtained from the 
optimization of ApoE primer pair 3 at  
annealing temperatures of 57˚C, 59˚C and 
61˚C 
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Figure 15. Representative image of the resulting bands obtained from a second optimization of the ApoE primer pair 3 
at annealing temperatures ranging from 64˚C to 69˚C. 
The resulting amplification showed complete absence of nonspecific bands and allowed to 
determine that 67°C was higher temperature limit for Primer pair 3 annealing. 
 
 
Figure 16. Representative image of the resulting bands obtained from the amplification of the 3’UTR of the ApoE gene 
of 19 samples using ApoE primer pair 3 and an annealing temperature of 67°C. 
When performing the PCR with the annealing temperature set at 67°C, the same 
nonspecific amplification occurred, even in samples that have previously resulted in specific 
products in the same conditions, such as D29 and D44. 
Since we were not able to devise alternative PCR conditions to this set of primers that 
would allow specific amplification for all samples, only samples that exhibited specific 
amplification under the latter conditions were submitted for sequencing. 
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4.2 APP 3’UTR sequencing and SNP detection 
Following 3’UTR amplification, all PCR products were purified and sequenced. 
All the sequences obtained from the control group for both the App and ApoE perfectly matched 
the documented 3’UTR sequences present on the NCBI and ENSEMBLE databases. 
Regarding the 3’UTR of the APP gene, a total of 9 potential heterozygous SNPs were 
detected in 2 samples from group 3 (with 3 of them being common between samples) and 1 
potential heterozygous SNP was detected in 1 sample from group 2. 
The App 3’UTR sequencing of subject D43 resulted in the detection of 6 potential 
heterozygous SNPs.  The localization and nucleotide substitutions of this subject were as follows: 
G16T (figure 18), G28A (figure 18), T43A (figure 19), C95A (figure 22), A1079C (figure 21) and 
G1116C (figure 22). 
 
Figure 18.  SNP detection via chromatographic analysis on the SEQUENCHER software.  The two top rows represent a 
fragment of the obtained sequence from D43 sequencing using primer Fw1 (duplicates). Locations of peak overlaps 
are framed by black lines. Guanine 16 shows an overlap with thymine and Guanine 18 shows an overlap with 
Adenine. The chromatogram of the third row was obtained using primer Fw1 on a new PCR product of D43’s App 
3’UTR and the chromatogram on the fourth row was obtained using primer Re 3 as means of SNP confirmation. No 
peak overlap was observed on the third and fourth rows. 
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Figure 19. SNP detection via chromatographic analysis on the SEQUENCHER software.  The two top rows represent a 
fragment of the obtained sequence from D43 sequencing using primer Fw1 (duplicates). Locations of peak overlaps 
are framed by black lines. Thymine 43 shows an overlap with adenine. The chromatogram of the third row was 
obtained using primer Fw1 on a new PCR product of D43’s App 3’UTR and the chromatogram on the fourth row was 
obtained using primer Re 3 in order to perform SNP confirmation. No peak overlap was observed in the third and 
fourth rows. 
 
Figure 20. SNP detection via chromatographic analysis on the SEQUENCHER software.  The two top rows represent a 
fragment of the obtained sequence from D43 sequencing using primer Fw1 (duplicates). Locations of peak overlaps 
are framed by black lines. Cytosine 95 shows an overlap with adenine. The chromatogram of the third row was 
obtained using primer Fw1 on a new PCR product of D43’s App 3’UTR and the chromatogram on the fourth row was 
obtained using primer Re 3 in order to perform SNP confirmation. No peak overlap was observed on the third and 
fourth rows. 
 
Figure 21. SNP detection via chromatographic analysis on the SEQUENCHER software.  The two top rows represent a 
fragment of the obtained sequence from D43 sequencing using primer Re1 (duplicates). Locations of peak overlaps 
are framed by black lines. Adenine 1079 shows an overlap with cytosine. The chromatogram of the third row was 
obtained using primer Re1 on a new PCR product of D43’s App 3’UTR in order to perform SNP confirmation and no 
peak overlap was observed.. 
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Figure 22. SNP detection via chromatographic analysis on the SEQUENCHER software.  The two top rows represent a 
fragment of the obtained sequence from D43 sequencing using primer Re1 (duplicates). Locations of peak overlaps 
are framed by black lines. Guanine 1116 shows an overlap with cytosine. The chromatogram of the third row was 
obtained using primer Re1 on a new PCR product of D43’s App 3’UTR in order to perform SNP confirmation and no 
peak overlap was observed. 
Subject D47 showed a total of 3 potential heterozygous SNP’s: C (figure 23), C95A (figure 
24) and G1116C (figure 25), all common to subject D43.  
 
Figure 23. SNP detection via chromatographic analysis on the SEQUENCHER software.  The two top rows represent a 
fragment of the obtained sequence from D47 sequencing using primer Fw1 (duplicates). Locations of peak overlaps 
are framed by black lines. Guanine 28 shows an overlap with adenine. The chromatogram of the third row was 
obtained using primer Fw1 on a new PCR product of D43’s App 3’UTR and the chromatogram on the fourth row was 
obtained using primer Re 3 in order to perform SNP confirmation. No peak overlap was observed on the third and 
fourth rows. 
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Figure 24. SNP detection via chromatographic analysis on the SEQUENCHER software.  The two top rows represent a 
fragment of the obtained sequence from D47 sequencing using primer Fw1 (duplicates). Locations of peak overlaps 
are framed by black lines Cytosine 95 shows an overlap with adenine. The chromatogram of the third row was 
obtained using primer Fw1 on a new PCR product of D43’s App 3’UTR and the chromatogram on the fourth row was 
obtained using primer Re 3 in order to perform SNP confirmation. No peak overlap was observed on the third and 
fourth rows. 
 
 
Figure 25. SNP detection via chromatographic analysis on the SEQUENCHER software.  The two top rows represent a 
fragment of the obtained sequence from D47 sequencing using primer Re1 (duplicates). Locations of peak overlaps 
are framed by black lines. Guanine 1116 shows an overlap with cytosine. The chromatogram of the third row was 
obtained using primer Re1 on a new PCR product of D43’s App 3’UTR in order to performSNP confirmation and no 
peak overlap was observed. 
In order to be confirmed as a SNP, a specific nucleotide change must be detected in the 
two independent PCR products and the peak overlap must be concordant. Furthermore, the 
mismatch location should exhibit similar peak overlap in both forward and reverse sequence 
reads.  
In order to validate the observed mismatches as SNPs, two additional primers were 
designed, since all the hypothetical mismatches detected on D43 and D47 were only covered by 
either the Fw1 primer or the Re1 primer 
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Figure 26. Primers Fw3 and Re3, used in the sequencing of App 3’UTR for SNP validation. Primer Fw3 was designed to 
provide a complementary sequence read to the primer Re1. Primer Re3 was designed to provide a complementary 
sequence read to the primer Fw1. 
The chromatographic results obtained from the confirmation assays, which 
consisted in re-sequencing with new PCR products and sequencing with primers Fw3 and 
Re3, showed no nucleotide overlaps in the locations previously hypothesized to bear 
heterozygous SNPs. 
However, the App 3’UTR sequencing of subject D39 resulted in the detection of 
another potential heterozygous SNP. A peak overlap of thymine and cytosine was 
detected in the position 310 of the 3’UTR when both primer Fw1 and Re2 were used. 
Further confirmation was achieved when a new PCR reaction and re-sequencing was 
performed, and provided concordant results, therefore validating this mismatch as a new 
SNP. 
 
Figure 27. SNP detection via chromatographic analysis on the SEQUENCHER software.  The two top rows represent a 
fragment of the obtained sequence from D39 sequencing using the primers Fw1 and Re2. Locations of peak overlaps 
are framed by black lines. Thymine 310 shows an overlap with cytosine. The chromatograms of the third and fourth 
row were obtaining using primers Fw1 and Re2 on a new PCR product of D39’s App 3’UTR as means of SNP 
confirmation. The cytosine peak remained coincident with the peak for thymine 310. 
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4.3 APP 3’UTR sequencing 
Sequencing of 3’UTR of ApoE was successfully performed on 4 control samples, 7 samples 
from group 2 and 14 samples from group 3. All the obtained sequences perfectly matched the 
3’UTR sequence displayed on both NCBI and ENSEMBLE, showing no evidence of the existence of 
mismatched SNPs (figure 28). 
 
Figure 17. Representative chromatographic analysis of the 3’UTR sequence of the ApoE gene using the SEQUENCHER 
software. The sequence was obtained using the primer Fw3 from the ApoE 3’UTR primer pair 3 set. The sequence of 
the 3’UTR is delimited by the two blue arrows. This particular sequence was obtained from D42. 
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4.4 Prediction of SNP effects on miRNA function 
The possible influence of the detected mismatches on miRNA binding to the 3’UTR of APP 
was determined by comparing the Watson-Crick base-pairing, predicted by microRNA.org 
database, between the App 3’UTR and miRNA sequences in both the presence of a SNP or in the 
standard alignment. 
The microRNA.org database analysis highlighted 6 miRNAs whose base pairing could likely 
be affected in the presence of a T → C polymorphism in the position 310 of the 3’UTR of APP. 
 
Figure 29. miRNAs predicted to bind in the vicinity of nucleotide 310 of the 3’UTR sequence of APP mRNA. The 
underlined nucleotide corresponds to the location of the detected T360C polymorphism. A green underline indicates 
that the SNP creates a Watson-Crick base pairing and a red underline signifies that the detected SNP compromises a 
Watson-Crick base pairing. 
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Although the validation results did not allow the consideration of the G16T substitution 
present in D43 as a valid SNP, the bioinformatic analysis highlighted this segment of the App 3’UTR 
as target for the higly conserverd has-miR-485-5p. 
 
Figure 30. Predicted alignment of miR-485-5p to the 3’UTR sequence of APP mRNA. The nucleotide underlined in red 
represents the location of the detected artifact in the first chromatograms of D43. If the artifact was validated as a 
SNP, its presence would impair the affinity of miRNA-485-5p towards the 3’UTR of APP miRNA. 
Since the binding of mir-485-5p to the 3’UTR of APP was predicted by several 
bioinformatics tools but was not, until the date, experimentally validated, we decided to perform a 
luciferase validation assay for this miRNA. 
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4.5 MiRNA target validation 
HEK 293T cells transfected simultaneously with the APP 3’UTR reporter plasmid (p3UTR) 
and the miRNA-485-5p expression plasmid exhibited a 49% decrease in luciferase activity with 
respect to the luciferase activity observed in the same cell line following transfection with p3UTR 
and a control plasmid encoding GFP. These results suggest that miR-485-5p is able to specifically 
bind to the 3’UTR of the APP mRNA, limiting the production of the luciferase protein.  
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Figure 31. Measurement of luciferase activity following HEK293T cell transfection. Hek293T cells were counted and 
plated one day before transfection with two distinct plasmid mixes. The cells received 1µg of pMir-485-5p and 1µg of 
APP 3’UTR reporter plasmid (p3UTR) or 1µg of pGFP and 1µg of APP 3’UTR reporter plasmid (p3UTR) complexed with 
the Lipofectamine LX transfection reagent. Transfection was performed during 4 hours. After this period the cells 
were washed and incubated for 48h with normal medium. Luciferase activity was measured in the cellular lysates 
following addition of ATP and luciferin. Luciferase activity is presented as CPS (counts per second) for the negative 
control (untransfected HEK293T) and for both plasmids mixes (HEK293T+pMir+p3UTR and HEK293T+pGFP+p3UTR). 
Results are representative of a single experiment with each condition performed in triplicate. 
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Discussion 
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5. Discussion 
Ninety-five percentof all AD patients present the sporadic form of the disease, indicating  that 
the large majority of AD casesare triggered by unknown causes. Currently, the only factor known 
to trigger AD is an increased gene dosage, which is found in only 5% of all AD patients and can 
have several genetic causes (familial AD).  
Over 500 genes have been proposed to detain AD ethiopathogenic relevance in the presence 
of genetic polymorphisms. In addition, several studies have shown that miRNA levels are  
deregulated in AD patients. In fact, a recent study was able to distinguish AD and control subjects 
with 93% accuracy trough miRNA profiling alone 48.   
With this in mind, we focused this project on revisiting the relevance of protein expression 
deregulation in AD in the presence of miRNA-related SNPs , aiming at taking part in the 
exploratory effort required to fully uncover the relevance of miRNAs in this multifactorial 
neuropathology. 
The last study to adress the influence of SNPs on miRNA binding, in the context of AD, was 
published in 2008. This study presented four specific SNPs detected in the 3’UTR region of APP and 
seven specific SNPs detected in the 3’UTR region of BACE1 in AD ptients. However, the detected 
polymorphisms were reported as non-determinant for miRNA binding affinity and, therefore, of no 
major relevance for AD progression 49. 
In 2011, Delay et al. set out to determine if the previously reported SNPs could, in fact, 
modulate miRNA function. This author was able to demonstrate that two of the previously 
overlooked SNPs could influence the binding of miRNA-147 and miRNA-20a to the APP 3’UTR. 
In this project, we were able to successfully sequence the 3’UTR of the APP gene in 12 healthy 
controls, 25 AD patients and 18 patients with MCI. The inclusion of an MCI group was made since 
it is assumed that the vast majority of these patients will develop AD. 
Our results culminated in the validation of one MCI patient-specific heterozygous SNP, on 
patient D39, which consisted in the nucleotide substitution of T → C in the position 310 of the 
3’UTR of APP. The bioinformatic analysis of this SNP highlighted five possible miRNAs whose 
function would likely be altered due to this base-pairing change: MiRNA-582-3p, miRNA-423-5p, 
miRNA-185*, miRNA-31* and miRNA-892b. 
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Four of this miRNAs (miRNA-582-3p, miRNA-423-5p, miRNA-185*, and miRNA-892b) were 
predicted to gain higher complementarity to the 3’UTR of the APP gene due to the presence of this 
polymorphism. The physiological relevance of such higher affinity was, however, predicted to be 
of no major significance since the nucleotide substitution provided an extra base pairing at a 
position outside of the seed region of miRNA-582-3p and miRNA-892b. As for miRNA-423-5p and 
miRNA-185*, the nucleotide substitution permuted an existent non-Watson-Crick base pairing 
between the uracil present at the mRNA of the APP and the guanine present at the miRNA to a 
Watson-Crick base pairing of cytosine and guanine which presents higher thermodynamic stability. 
However, these changes were located outside of the seed region of both miRNAs and, therefore, 
their contribution to the overall binding affinity of the miRNAs towards the APP mRNA is limited. 
Regarding miRNA-31*, this polymorphism was predicted to compromise the miRNA 
complementarity with the APP mRNA since it affects base pairing within the seed region. It would 
be interesting to assess the impact that the complementarity hindrance created by this SPN could 
have on APP translation and its contribution to the development of mild cognitive impairment and 
to a possible progression to AD. MiRNA-31* was already demonstrated to be physiologically 
relevant in the context of Oral Leukoplakia 50 and could, therefore, provide some degree of 
regulation of the APP protein. 
During the progress of our study, several other SNP candidates were detected (figure 31) 
but were considered to be false-positives due to the presence of non-concordant peak overlaps in 
the chromatographic analysis. However, one of these potential  SNPs,  was particularly interesting, 
taken into consideration the influence that one highly conserved miRNA, miRNA-485-5p , 
predicted to bind to  3’UTR  region were the mismatch was located, could have on the regulation 
of APP. MiRNA-485-5p has already been shown to be downregulated in AD and was validated as 
strong regulator of BACE1, one of the key proteins involved in AD 51. 
We determined the possible influence of miRNA-485-5p on APP expression by 
simultaneously transfecting HEK293T cells with a miRNA-458-5p expressing plasmid and with a 
APP 3’UTR luciferase reporter plasmid, were the luciferase gene is under the control of the same 
promoter of the 3’UTR. This procedure assessed the degree of posttranscriptional regulation that 
this miRNA can have on APP. Our results showed that in the absence of the miRNA-458-5p 
expressing plasmid, the transfected cells yielded a decrease of 61% in luciferase activity with 
respect to cells transfected with the 3’UTR plasmid and a control plasmid encoding GFP. Since the 
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total luciferase activity is proportional to the amount of expressed luciferase, these results 
provided compelling evidence that miRNA-485-5p is able to bind to the 3’UTR of the APP gene and 
regulate APP translation.   
 
Figure 31. Overview of the location of the artifact signals and the validated SNP detected in this study in the 3’UTR 
sequence of the APP gene.. The primer sequences are highlighted in bold. Each of the red circular frames represents 
the location of one of the peak artifacts and the green circular frame represents the location of the validated T360C 
heterozygotic polymorphism. The frame marked with the asterisk highlights the location of miRNA-485-5p binding.  
Our results from ApoE 3’UTR sequencing did not provide any evidence of existing SNPs 
and were fairly limited due to the number of sequencing-usable samples.  The discrepancy 
observed in the PCR product specificity obtained in different PCR reactions for the same samples 
excludes that the specific amplification failure might be due to inherent characteristics of the 
genome of each subject. The PCR conditions  were replicated in three different thermocyclers and 
unspecific amplification occurred even when new aliquots of reaction buffer, DNA polymerase, 
MgCl2, H2O, dNTP’s and primers were used for the master mix.  
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6. Conclusions and future perspectives 
Given the exploratory nature of this project, the obtained results were not sufficient to 
determine whether SNPs in the 3’UTR region of the APP and ApoE genes are playing a significant 
role on AD ethiopathology. 
There is a possibility that the detected SNP on D39 could in fact result in a diminished 
translational inhibition of the mRNA of APP, contributing to the escalation of the diagnosed 
cognitive impairment. This possibility could promptly be tested trough the previously described 
transfection and luciferase assays. It would also be interesting to accompany the symptomatic 
development of this patient in order to determine if this polymorphism could drive the full 
installment of AD. 
The significance of SNPs influence on miRNA function in the AD context can still arise from 
other genes strongly related to this pathology.  BACE1 and PSEN-1 are prime examples of such 
genes that couldn not be approached on this study due to the extensive length of their 3’UTR 
regions comprising 3865nt and 4401nt, respectively. Next-generation sequencing is likely the best 
approach to tackle such lengthy sequences and further elucidate the true impact that genetic 
variability can have on AD.  
To the best of our knowledge, this is the first time that miRNA-485-5p binding to the APP 
3’UTR has been validated experimentally. We strongly believe that, in light of the strong pairing 
between miRNA-485-5p and the APP mRNA, the upregulation of this miRNA in the brain tissue 
could contribute to the decrease of APP expression, constituting an interesting new therapeutic 
strategy for Alzheimer’s disease. 
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